Evidence map›Paper›PMID 34140100›Full record

ReviewSeminars in nephrology2021

Glucose Homeostasis, Hypoglycemia, and the Burnt-Out Diabetes Phenomenon in Kidney Disease.

Connie M Rhee, Csaba P Kovesdy, Kamyar Kalantar-Zadeh

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Seminars in nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05509881 (Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05509881 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial

TypeinterventionalSponsorUniversity of California, IrvineRan2023 to 2026Enrolled122ConditionsHemodialysis, Diabete Mellitus, Continuous Glucose MonitoringArmsContinuous glucose monitoring (CGM), Usual care (Self-monitored blood glucose)
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Connie M RheeHarold Simmons Center for Chronic Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine, Orange, CA. Electronic address: crhee1@uci.edu.
Csaba P KovesdyDivision of Nephrology, University of Tennessee Health Science Center, Memphis, TN; Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, VA.
Kamyar Kalantar-ZadehHarold Simmons Center for Chronic Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine, Orange, CA; Nephrology Section, Tibor Rubin Veterans Affairs Long Beach Healthcare System, Long Beach CA.
University of California, Irvine · USMemphis VA Medical Center · US

Funding

A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis PatientsR01DK122767 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RHEE, CONNIE MEEYOUNG · 2019 to 2023
$3.3M
Defining Optimal Transitions of Care in Advanced Kidney Disease: Conservative Management vs. Dialysis ApproachesR01DK124138 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KALANTAR-ZADEH, KAMYAR, RHEE, CONNIE MEEYOUNG · 2020 to 2024
$2.9M
Transition of Care in CKD (TC-CKD)U01DK102163 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI JACOBSEN, STEVEN J, KALANTAR-ZADEH, KAMYAR · 2014 to 2018
$2.8M
MALNUTRITION, DIET AND RACIAL DISPARITIES IN CKDK24DK091419 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI KALANTAR-ZADEH, KAMYAR · 2011 to 2020
$1.8M
Novel Saliva-based Renal Function Test PlatformR44DK116383 · NIDDK · INTELLIGENT OPTICAL SYSTEMS, INC. · PI KALANTAR-ZADEH, KAMYAR, NGUYEN, TRONG · 2018 to 2020
$1.7M
A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis PatientsR03DK114642 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI RHEE, CONNIE MEEYOUNG · 2017 to 2018
$155k
NIDDK NIH HHS K24 DK091419NIDDK NIH HHS R01 DK122767NIDDK NIH HHS R01 DK124138NIDDK NIH HHS R03 DK114642NIDDK NIH HHS R44 DK116383NIDDK NIH HHS U01 DK102163
6 · The paper itself

Abstract

Chronic kidney disease (CKD) is among the most prevalent and dire complications of diabetes mellitus in adults across the world. Diabetes substantially contributes to the burden of kidney disease, such that one third to one half of CKD in the United States and many other countries is attributable to diabetic kidney disease (DKD). As DKD progresses to end-stage renal disease (ESRD), patients are at heightened risk for atypical glycemic complications, including the development of burnt-out diabetes, manifested by hypoglycemic bouts and poor outcomes. Furthermore, even in the absence of diabetes, hypoglycemia is a frequent occurrence in CKD patients that may contribute to their high burden of cardiovascular disease and death. Extrapolation of data from clinical trials in high-cardiovascular-risk populations and observational studies in patients with non-dialysis-dependent (NDD) CKD and ESRD suggest that moderate glycemic targets defined by glycated hemoglobin levels of 6% to 8% and glucose levels of 100 to 150 mg/dL are associated with better survival in DKD patients. However, given the imprecision of glycated hemoglobin levels in kidney disease, further research is needed to determine the optimal glycemic metric and target in diabetic NDD-CKD and ESRD patients. Given their exceedingly high cardiovascular morbidity and mortality, there is a compelling need for further investigation of how to optimally manage dysglycemia in the NDD-CKD and ESRD populations.

Indexed as

Diabetes MellitusDiabetic NephropathiesHypoglycemiaBlood GlucoseHomeostasisHumansHypoglycemic AgentsUnited StatesBlood GlucoseHypoglycemic Agents

Identifiers

PMID34140100
PMCPMC8221113
OpenAlexW3169753179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.